Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluad vs Non-adjuvanted Influenza Vaccine in Adults ≥65 Years
NCT06087640Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 21
01
Overview
A Phase 3 trial of adjuvanted trivalent subunit influenza vaccine in influenza, sponsored by CSL Seqirus. Started Oct 2023; status: completed.
02
Drugs
adjuvanted trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06087640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087640.